| pubmed-article:18249537 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18249537 | lifeskim:mentions | umls-concept:C0812228 | lld:lifeskim |
| pubmed-article:18249537 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:18249537 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:18249537 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:18249537 | pubmed:dateCreated | 2008-2-18 | lld:pubmed |
| pubmed-article:18249537 | pubmed:abstractText | This communication reports a new synthetic route of pyridopyrimidines to facilitate their structural optimization in a library fashion and describes the development of pyridopyrimidines that have excellent enzymatic and cell potency against Akt1 and Akt2. This series also shows a high level of selectivity over other closely related kinases and significantly improved caspase-3 activity with the more optimized compounds. | lld:pubmed |
| pubmed-article:18249537 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18249537 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18249537 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18249537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18249537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18249537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18249537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18249537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18249537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18249537 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18249537 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18249537 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:18249537 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:HartmanGeorge... | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:RobinsonRonal... | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:HuberHans EHE | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:BilodeauMark... | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:WuZhicaiZ | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:HartnettJohn... | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:JonesRaymond... | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:NeilsonLou... | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:FuShengS | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:BarnettStanle... | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:Defeo-JonesDe... | lld:pubmed |
| pubmed-article:18249537 | pubmed:author | pubmed-author:KralAstrid... | lld:pubmed |
| pubmed-article:18249537 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18249537 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18249537 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:18249537 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18249537 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18249537 | pubmed:pagination | 1274-9 | lld:pubmed |
| pubmed-article:18249537 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:meshHeading | pubmed-meshheading:18249537... | lld:pubmed |
| pubmed-article:18249537 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18249537 | pubmed:articleTitle | Development of pyridopyrimidines as potent Akt1/2 inhibitors. | lld:pubmed |
| pubmed-article:18249537 | pubmed:affiliation | Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., PO Box 4, West Point, PA 19486, USA. | lld:pubmed |
| pubmed-article:18249537 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:18249537 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18249537 | lld:pubmed |
